ITAILD
Pietro Invernizzi
Pietro Invernizzi obtained his Doctor of Medicine degree in July 1993 from the University of Milan.
His clinical and scientific journey commenced in 1993, and in December 1996, he earned his PhD in Gastroenterology from the University of Milan.
During his doctoral period, he worked as a researcher at Clinical Mass Spectrometry, Children’s Hospital Medical Center, Cincinnati, OH, USA.
In 2000, he successfully completed his four-year Gastroenterology training at the University of Milan, achieving specialist qualification in gastroenterology. From 2000 to 2008, he served as a Clinical Assistant Professor at the Division of Internal Medicine and the Hepatology Unit of the San Paolo Hospital of the University of Milan.
From 2008 to 2015, Dr. Invernizzi served as the head of the Center for Autoimmune Liver Diseases at Humanitas Clinical and Research Center, Rozzano (Milan), Italy.
Between 2007 and 2016, he concurrently held a position as an Assistant Professor in the Department of Internal Medicine, Division of Rheumatology, Allergy and Clinical Immunology, School of Medicine, University of California at Davis, CA, USA. Since December 2015, Dr. Invernizzi has held the position of Professor in Gastroenterology at the University of Milano-Bicocca (achieving Full Professor status in September 2020). Since December 2016, he has been the head of the Division of Gastroenterology and Center for Autoimmune Liver Diseases at San Gerardo Hospital, Monza, Italy.
Dr. Invernizzi has co-authored 322 original publications in peer-reviewed journals, accumulating a total of 13,245 citations and boasting an H-index of 62. His articles have been featured in leading scientific journals such as the New England Journal of Medicine, Nature Genetics, The Lancet, Ann Intern Med, Gastroenterology, Journal of Hepatology, Hepatology, and J Immunol. Additionally, Dr. Invernizzi has authored 28 book chapters.
His areas of scientific expertise lie in liver diseases, with a particular focus on rare autoimmune liver diseases such as primary biliary cirrhosis (PBC), primary sclerosing cholangitis (PSC), autoimmune hepatitis (AIH), and their overlaps. More recently, he has expanded his interests to include biliary and neuroendocrine tumors.
ITAILD
Marco Carbone
Dr Carbone is Associate Professor at the University of Milan-Bicocca and Medical Director of the ASST Grande Ospedale Metropolitano Niguarda in Milan.
He graduated in Medicine in Rome and specialised in Hepatology in Italy and the UK.
His main research interest is the study of pathological mechanisms in cholestatic liver diseases. He graduated in Rome and continued his training in Hepatology in the UK, where he completed his PhD on cholestatic liver diseases at the Department of Medical Genetics at the University of Cambridge.
His research focuses on the mechanisms underlying chronic cholestatic diseases, primary sclerosing cholangitis and primary biliary cholangitis. He is a board member of the Globe PBC Study Group, Vice-Chair of the PBC Foundation UK and co-founded the Italian Autoimmune Liver Disease Registry with Prof. He has received prestigious research grants from the Ministry of Health (Ricerca Finalizzata), the Ministry of Universities (PRIN), the Italian Association for the Study of the Liver (AISF), the European Association for the Study of the Liver (EASL). In 2021 he received the prestigious ‘Rising Star’ award from the United European Gastroenterology (UEG). He is Associate Editor of Digestive and Liver Disease, sits on the Editorial Board of Hepatology and is the author of more than 130 scientific articles (h-index 31).
ITAILD
Fabio Piscaglia
Full Professor of Internal Medicine at the University of Bologna.
Director of the Department of Internal Medicine, Hepatobiliary Diseases, and Immunoallergology at IRCCS AUO Bologna.
Director of the School of Specialization in Internal Medicine at the University of Bologna.
Specialist in Internal Medicine with a Ph.D. in Ultrasound in Medicine and Biology from the University of Bologna.
International experience includes one year of basic research in a laboratory at the University of Göttingen, Germany.
Areas of interest and research include hepatocellular carcinoma, liver transplantation, chronic liver disease, portal hypertension, and abdominal ultrasound.
Served as the President of the European Federation of Societies of Ultrasound in Medicine and Biology (www.efsumb.org) from 2011 to 2013.
Was a member of the Coordinating Committee of the Italian Association for Liver Studies from 2008 to 2011.
Acting as a Visiting Professor at the University of Cluj Napoca in Romania since 2018.
Coordinator of the Italian Multisociety Guidelines on Hepatocellular Carcinoma published in 2016 (https://areasoci.sirm.org/download/1923).
Contributed to the writing committee for the European Association for the Study of the Liver (EASL) guidelines on hepatocellular carcinoma (Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol. 2018 Jul;69(1):182-236). J Hepatol. 2018 Jul;69(1):182-236).
Author of nearly 400 publications in PubMed.
H-index values of 63 in Clarivate and 90 in Google Scholar, ranking among the top 100 Italian scientists in terms of H-index value in the field of Clinical Sciences on the Top Italian Scientists.
ITAILD
Antonio Moschetta
Antonio Moschetta, born in 1973, holds the position of Full Professor of Internal Medicine and serves as the Coordinator of the PhD program “Metabolism, Aging, and Social Medicine” at the University of Bari “Aldo Moro.”
Previously, he served as the Director of the School of Internal Medicine Residency (2017-2020) and as the President of the Graduate School of Medicine at the University of Bari “Aldo Moro” (2015-2019). After obtaining his medical degree in Bari, Italy, he worked as a researcher in Spain for a year and then spent three years in the Netherlands at the University of Utrecht, where he earned his Ph.D. Subsequently, he devoted four years to research in Texas at the University of Dallas under the guidance of Nobel laureate in pharmacology, Prof. Al Gilman. Upon returning from the United States, he initially led the Department of Translational Pharmacology at the Mario Negri South Institute in Abruzzo, Italy (2010-2013) and later served as the Scientific Director of the IRCCS “Giovanni Paolo II” in Bari, Italy (2013-2014). His significant contributions in the fields of nutrients, metabolism, and DNA include the identification of the intestinal hormone FGF19 and the antitumor role of the nuclear receptor FXR. Antonio Moschetta has received numerous national and international awards, including the Best Researcher award from the Italian Society of Internal Medicine in 2000, the Italian Society of Gastroenterology in 2002, and the Italian Association for the Study of the Liver in 2003. He has also been honored with prestigious awards such as the European Lipid Award in Gothenburg, Sweden, the David Williams Award in Colorado, and the Richard Weizmann Award in San Francisco. In 2017, he was appointed Knight of the Order of Merit of the Italian Republic for scientific merit.
Since 2022, he has been a member of the United European Gastroenterology Research Committee. Additionally, he serves on the review boards of several international funding agencies and editorial boards of numerous scientific journals. Antonio Moschetta directs both national and international research projects. He has authored over 180 scientific publications in international indexed journals, accumulating a total impact factor of more than 1,200, a personal H-index of 49, and more than 11,500 citations (Scopus). Furthermore, he is the author of three best-selling scientific, educational, and popular books published by Mondadori.
ITAILD
Vincenza Calvaruso
Vincenza Calvaruso is an associate professor of gastroenterology at the University of Palermo and the medical director at the Gastroenterology Unit of Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone Hospital in Palermo. She graduated from the University of Palermo in 2003 and completed her residency in Gastroenterology at the same university in 2007. From 2007 to 2008, she undertook clinical and research work in the field of hepatology at the Royal Free Hospital in London.
Currently, she serves as the secretary of the Italian Association for the Study of the Liver (AISF) and is a member of scientific associations such as the European Association for the Study of the Liver (EASL). Additionally, she is a member of the Sicily Region Hepatology Network SINTESI and serves as the web coordinator of the Sicilian Primary Biliary Cholangitis (PBC) network.
As a member of the Scientific Committee of the Baveno Cooperation, she participated in drafting the latest recommendations of the Consensus on Portal Hypertension (Baveno VII).
Dr. Calvaruso has actively contributed to research projects funded by the Ministry of Health (Finalized Research) and is a member of the extended partnership HEAL ITALY under PNRR funds, dedicated to research and innovation in the field of Precision Medicine.
Her primary areas of interest and research include cirrhosis and portal hypertension, noninvasive assessment of liver damage, autoimmune liver diseases, and viral hepatitis. She has authored more than 130 publications indexed on PubMed, boasting an h-index of 41.
Partners
